Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus (2022)
- Authors:
- USP affiliated authors: BORBA NETO, EDUARDO FERREIRA - FM ; SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; KUPA, LEONARD DE VINCI KANDA - FM ; KALLAS, ESPER GEORGES - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
- Unidade: FM
- DOI: 10.1002/acr.24824
- Subjects: ANTICORPOS; VACINAS VIRAIS; COVID-19
- Agências de fomento:
- Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
- Conselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)
- B3 -Bolsa de Valores do Brasil. Instituto Butantan, Sao Paulo, Brazil
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Arthritis care & research
- ISSN: 2151-464X
- Volume/Número/Paginação/Ano: v. 74, n. 4, p. 562-571, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
YUKI, Emily F. N et al. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis care & research, v. 74, n. 4, p. 562-571, 2022Tradução . . Disponível em: https://doi.org/10.1002/acr.24824. Acesso em: 03 maio 2024. -
APA
Yuki, E. F. N., Borba Neto, E. F., Pasoto, S. G., Seguro, L. P., Lopes, M., Saad, C. G. S., et al. (2022). Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis care & research, 74( 4), 562-571. doi:10.1002/acr.24824 -
NLM
Yuki EFN, Borba Neto EF, Pasoto SG, Seguro LP, Lopes M, Saad CGS, Silva CAA da, Kupa L de VK, Kallas EG, Bonfa ESD de O. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus [Internet]. Arthritis care & research. 2022 ; 74( 4): 562-571.[citado 2024 maio 03 ] Available from: https://doi.org/10.1002/acr.24824 -
Vancouver
Yuki EFN, Borba Neto EF, Pasoto SG, Seguro LP, Lopes M, Saad CGS, Silva CAA da, Kupa L de VK, Kallas EG, Bonfa ESD de O. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus [Internet]. Arthritis care & research. 2022 ; 74( 4): 562-571.[citado 2024 maio 03 ] Available from: https://doi.org/10.1002/acr.24824 - Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Short-term Accrual 2019 European League Against Rheumatism/American College of Rheumatology Domains and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage in Lupus Patients With and Without Nephritis at Disease Onset
- SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
- Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)
- 2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- Predictive factors according to type of infection in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, latin-american cohort
Informações sobre o DOI: 10.1002/acr.24824 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
